CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
ONCOTHERANOSTICS aims to develop a novel theranostic agent that combines cancer treatment and monitoring. By targeting specific tumor genes with small interfering RNA, it seeks to enhance immune response and improve personalized cancer therapies.
Despite significant advances in recent years, cancer remains the 2nd cause of death globally.
Immunotherapy is an exciting new therapeutic approach that triggers natural immune response against cancer cells.
Theranostics is an emerging therapeutic intervention, that uses dual (or multiple) purpose nanomedine, combining diagnostic and therapeutic effects within a single multifaceted formulation. ONCOTHERANOSTICS proposes the use of a novel theranostic agent to target key tumoral genes by siRNA a…
AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
United States, Baltimore
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
